Vanutide Cridificar
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 28 trials · 2 missed | ||||||
| Phase 2 | NCT01227564 | Feb 2011 → Feb 2014 | Alzheimer disease | Pfizer | Completed | Missed primary |
| Phase 2 | NCT01284387 | Jan 2011 → Jan 2014 | Alzheimer disease | JANSSEN Alzheimer Immunotherapy Research & Development, LLC | Completed | Missed primary |
| Phase 2 | NCT01238991 | Dec 2010 → Dec 2013 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00955409 | Nov 2009 → Dec 2013 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00959192 | Aug 2009 → Jan 2013 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00960531 | Jul 2009 → Dec 2013 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00752232 | Dec 2008 → Jul 2012 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00498602 | Nov 2007 → Feb 2013 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00479557 Comparator | May 2007 → Jan 2013 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vanutide cridificar | “Vanutide cridificar (ACC-001), an immunotherapeutic vaccine, is a potentially disease-modifying therapy that aims to reduce brain amyloid-β (Aβ) plaques in patients with...” PMID 26967206 ↗ 20164“To avoid this safety issue, an aminoterminal Aβ1-7 peptide conjugate, vanutide cridificar (ACC-001), was designed and is currently in clinical development.” PMID 25731629 ↗ 2015 “an aminoterminal Aβ1-7 peptide conjugate, vanutide cridificar (ACC-001), was designed and is currently in clinical development.” PMID 25731629 ↗ 2015 “Vanutide cridificar (ACC-001), an immunotherapeutic vaccine, is a potentially disease-modifying therapy” PMID 26967206 ↗ 2016 “Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18” NCT00955409 ↗ |
| Known as | ACC-001 | “To avoid this safety issue, an aminoterminal Aβ1-7 peptide conjugate, vanutide cridificar (ACC-001), was designed and is currently in clinical development.” PMID 25731629 ↗ 20158“Vanutide cridificar (ACC-001), an immunotherapeutic vaccine, is a potentially disease-modifying therapy” PMID 26967206 ↗ 2016 “Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18” NCT00955409 ↗ |
| Known as | Vanutida cridificar | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108058 ↗ |
| Action | Inhibit | “aims to reduce brain amyloid-β (Aβ) plaques” PMID 26967206 ↗ 2016 |
| Modality | Vaccine | “Vanutide cridificar (ACC-001), an immunotherapeutic vaccine” PMID 26967206 ↗ 2016 |
| Route | Intramuscular | “Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12” NCT00479557 ↗ |
| Target | APP | “Amyloid-beta A4 protein vaccine antigen” CHEMBL2108058 ↗ |